Momordica charantia Administration Improves Insulin Secretion in Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
An improvement in parameters of glycemic control has been observed with Momordica charantia in patients with type 2 diabetes mellitus (T2DM). It is unknown whether this improvement is through a modification of insulin secretion, insulin sensitivity, or both. We hypothesized that M. charantia administration can improve insulin secretion and/or insulin sensitivity in patients with T2DM, without pharmacological treatment. The objective of the study was to evaluate the effect of M. charantia administration on insulin secretion and sensitivity. A randomized, double-blinded, placebo-controlled, clinical trial was carried out in 24 patients who received M. charantia (2000 mg/day) or placebo for 3 months. A 2-h oral glucose tolerance test (OGTT) was done before and after the intervention to calculate areas under the curve (AUC) of glucose and insulin, total insulin secretion (insulinogenic index), first phase of insulin secretion (Stumvoll index), and insulin sensitivity (Matsuda index). In the M. charantia group, there were significant decreases in weight, body mass index (BMI), fat percentage, waist circumference (WC), glycated hemoglobin A1c (A1C), 2-h glucose in OGTT, and AUC of glucose. A significant increase in insulin AUC (56,562 ± 36,078 vs. 65,256 ± 42,720 pmol/L/min, P = .043), in total insulin secretion (0.29 ± 0.18 vs. 0.41 ± 0.29, P = .028), and during the first phase of insulin secretion (557.8 ± 645.6 vs. 1135.7 ± 725.0, P = .043) was observed after M. charantia administration. Insulin sensitivity was not modified with any intervention. In conclusion, M. charantia administration reduced A1C, 2-h glucose, glucose AUC, weight, BMI, fat percentage, and WC, with an increment of insulin AUC, first phase and total insulin secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603
Assessment of insulin sensitivity/resistance
Gutch, M., Kumar, S., Razi, S., Gupta, K., & Gupta, A. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.146874 · Cited by 555 · cited 1×
“32 Several clinical trials have reported the hypoglycemic effect of M. charantia in patients with T2DM.”
Cited by
Alam, S., Sarker, M. M. R., Sultana, T. N., Chowdhury, M. N. R., Rashid, M. A., Chaity, N. I., Zhao, C., Xiao, J., Hafez, E. E., Khan, S. A., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.800714 · Cited by 349
Peter, E. L., Kasali, F. M., Deyno, S., Mtewa, A., Nagendrappa, P. B., Tolo, C. U., Ogwang, P. E., & Sesaazi, D. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.10.033 · Cited by 96
Kim, S. K., Jung, J., Jung, J. H., Yoon, N., Kang, S. S., Roh, G. S., & Hahm, J. R. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102524 · Cited by 79
Geck, M. S., Cristians, S., Berger-González, M., Casu, L., Heinrich, M., & Leonti, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01160 · Cited by 74
“months decreased a range of parameters associated with diabetes such as BW, BMI, waist circumference, fat percentage, glycated hemoglobin A1c, 2-h glucose in the oral glucose tolerance test and glucose in parallel to an increase in insulin secretion (Cortez-Navarrete et al., 2018).”
BackgroundKrawczyk, M., Burzynska-Pedziwiatr, I., Wozniak, L. A., & Bukowiecka-Matusiak, M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44020049 · Cited by 28
Metadata
- Authors
- Cortez-Navarrete, M., Martínez-Abundis, E., Pérez-Rubio, K. G., González-Ortiz, M., & Méndez-del Villar, M.
- Venue
- Journal of Medicinal Food
- Publisher
- SAGE Publications
- Published
- 2018-07
- Volume
- 21
- Issue
- 7
- Pages
- 672-677
- ISSN
- 1096-620X (ISSN-L)
- 1557-7600
- OpenAlex
- W2786640815
- Cited by
- 107
- References
- 3
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.